To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

ESBL-producing gram negative Enterobacteria is becoming more prevalent, and carbapenems play a key role in combating against ESBL for complicated urinary tract infections (cUTI). However, carbapenems are only available intravenously in the U.S. FDA is currently reviewing the newly developed oral carbapenems (sulopenem and tebipenem) and have requested additional clinical trial information before granting approval for cUTI. Currently available phase 3 clinical trials for tebipenem and sulopenem are reviewed.

Disciplines

Clinical Trials | Medical Education | Medical Sciences | Medicine and Health Sciences

Download

Share

COinS
 

Oral Sulopenem and Tebipenem for Complicated Urinary Tract Infection and Pyelonephritis in patients with Extended-Spectrum Beta-Lactamase (ESBL)-producing Gram Negative, Susceptible Bacteria

ESBL-producing gram negative Enterobacteria is becoming more prevalent, and carbapenems play a key role in combating against ESBL for complicated urinary tract infections (cUTI). However, carbapenems are only available intravenously in the U.S. FDA is currently reviewing the newly developed oral carbapenems (sulopenem and tebipenem) and have requested additional clinical trial information before granting approval for cUTI. Currently available phase 3 clinical trials for tebipenem and sulopenem are reviewed.